Tag Archive for: Swedish

Approved antibody drug conjugate against different B-cell cancers ©ADC therapeutics SA

Swedish SOBI awarded rights to market Zynlonta from ADC therapeutics

In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.

Read more